December 17, 2020 -- iMetabolic Biopharma has announced an expansion of its partnership with Ligand Pharmaceuticals that will give it access to Ligand's OmniAb antibody discovery technology.
The deal will help iMetabolic speed development of therapeutic candidate molecules through its iPlatform technology for its peptide modulated fusion protein drug pipeline, it said. The molecules discovered on iPlatform using OmniAb are selectively engineered to improve target pathogen binding, and to elicit specific biological function for enhanced efficacy, clearance, and administration. Specifically, the technology will be used to advance iMetabolic's lead product, iMBP-001. OmniAb is an antigen production platform consisting of the following transgenic animals: OmniRat, OmniMouse, OmniFlic, OmniClic, OmniTaur, and OmniChicken.
Copyright © 2020 scienceboard.net